DLX6 and metastatic malignant neoplasm in the lymph nodes: As shown in Table 2, high expression of DLX6-AS1 was significantly associated with tumor size (OR: 1.32, 95% CI: 1.07–1.62; Figure 2A), tumor stages (OR: 1.94, 95% CI: 1.64–2.30; Figure 2B), lymph node metastasis (OR: 1.63, 95% CI: 1.35–1.97; Figure 2C) and distant metastasis (OR: 1.69, 95% CI: 1.19–2.41; Figure 2D).